2011? I really don't care about how many patents the company has issued. I care about one thing and they are failing BADLY on that front.
Idera Pharmaceuticals Announces Several Key Leadership Additions
CAMBRIDGE, Mass. and EXTON, Pa., Nov. 30, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced several key leadership additions as the company continues to build the organization to support its clinical development initiatives and organizational growth. Idera has appointed Mark J. Cornfeld, M.D., M.P.H., as Vice President and Medical Lead, Oncology; Kirsten L. Gruis, M.D., M.S., as Senior Medical Director, Rare Diseases; Tanya N. Lewis, Vice President, Regulatory Affairs and Quality Assurance and John J. Kirby, Vice President, Corporate Accounting.
"As we pursue our purpose of helping patients suffering from cancer or rare diseases, it is imperative that we continue to recruit outstanding talent," stated Vincent Milano, Idera Pharmaceuticals Chief Executive Officer. "Mark, Kirsten, Tanya and John are all highly qualified in their respective areas of expertise and of equal importance are perfect fits for the culture that we are building at Idera."
Dr. Cornfeld most recently served in various oncology leadership roles at GSK including lead physician for afuresertib and clinical development lead as well as Director of Global Oncology Research and Development. Prior to joining GSK, Dr. Cornfeld also held roles of increasing responsibility at Johnson & Johnson and Hoffman-LA Roche. Prior to joining industry, Dr. Cornfeld held oncology leadership roles at several medical centers including the Fox Chase Cancer Center in Philadelphia, PA. Dr. Cornfeld received his M.D. from the University of Pennsylvania, M.P.H. from Rutgers University and his Bachelor of Arts from the University of Pennsylvania.
Dr. Gruis most recently served as Director, Clinical Development at Alnylam Pharmaceuticals where she served as clinical lead for the Phase 3